戻る Agenda
Session 4, Track B: Decentralized Clinical Trials – Canada’s First Case Study and Next Steps
Session Chair(s)
Stephanie Anderson, MS
Associate Director, Regulatory Affairs, Intrinsik Corp., Canada
The global COVID-19 pandemic has catalyzed substantial advancements in the establishment and execution of decentralized clinical trials (DCTs) in Canada. This session will offer a glimpse into the experiences and findings from Canada’s first fully decentralized trial. Furthermore, we will delve into a proposed framework for hybrid DCTs, sharing experiences to date, lessons learned, and a vision for the future. Keeping our commitment to patient-centricity, we will also discuss the perceived advantages and challenges of DCTs from the perspectives of patients, caregivers, and their families.
Learning Objective : At the conclusion of this session, participants should be able to:- Describe different DCT models and understand methods to implement them
- Discuss the advantages and challenges with implementing DCTs
- Recognize the patient perspective when implementing DCTs
Speaker(s)
Aneta Woroniecka-Osio, MD
Manager, SCI, Bayer, Canada
Operational Implementation of Decentralized Clinical Trials advances participant-centric research
Roel Schlijper-Bos
Clinical Research Unit Manager , BC Cancer, Canada
Decentralized Clinical Trials – BC Cancer Perspective and Experiences
Maureen Smith, Med
Member, Clinical Trials Ontario College of Lived Experience, Canada
Patient and Public Perceptions in Canada About Decentralized and Hybrid Clinical Trials: “It’s About Time We Bring Trials to People”
Emily I McIntosh, PhD
College of Lived Experience Member, Clinical Trials Ontario, Canada
Patient and Public Perceptions in Canada About Decentralized and Hybrid Clinical Trials: “It’s About Time We Bring Trials to People”
Dawn P. Richards, PhD
Director, Patient and Public Engagement, Clinical Trials Ontario, Canada
Participant Perception of Decentralized Clinical Trials and Next Steps